Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-HGG-2013 Phase III trial of valproic acid added to temozolomide-based radiochemotherapy in pediatric high-grade glioma, DIPG, and gliomatosis cerebri
NL-OMON54159Phase 3Recruiting
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of valproic acid in glioma, diffuse intrinsic pontine glioma (DIPG) and gliomatosis cerebri (GC) (2 arms), sponsored by Georg-August-Universität Göttingen. Primary endpoint: Event-free survival. Started Oct 2023; status: recruiting.
02
Drugs
valproic acid
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)gliomatosis cerebri (GC)
Beyond the preview
Go deeper on NL-OMON54159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54159.